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W
e read with interest the debate about liver toxicity of
infliximab in psoriatic arthritis (PsA).1 2 We describe
the case of a 53 year old woman with a 4 year
history of refractory PsA who developed transaminasitis
during infliximab treatment.
CASE REPORT
Despite combination treatment (ciclosporin 300 mg/day,
fluocortolone 10 mg/day, and methotrexate (MTX)15 mg/
week intramuscularly), disease activity was still high, and
intravenous infliximab at 3 mg/kg was administered initially
at weeks 0, 2, 6, 14 and then every 6 weeks. Ciclosporin was
withdrawn.
Within 3 weeks she improved, fluocortolone was gradually
stopped while methotrexate (MTX) 20 mg/week intramuscu-
larly, was continued. After the sixth infusion, she developed a
mild transaminasitis and MTX, initially tapered, was stopped.
After the eighth infusion transaminases continued to rise and
in the absence of any other plausible cause, infliximab was
withdrawn.
She was admitted to our department with persistently high
values of aspartate aminotransferase and alanine amino-
transferase and a flare of PsA.
The erythrocyte sedimentation rate was 30 mm/1st h, C
reactive protein 170 mg/l, aspartate aminotransferase 143 IU
(normal 5–40), alanine aminotransferase 234 IU (normal 5–
55), anti-parietal cell antibodies and liver and kidney
microsomal antigen were absent, and serology for hepatitis
viruses, cytomegalovirus and Epstein-Barr virus, was
negative. The new appearance of anti-dsDNA (IgG) 1/20
(indirect immunofluorescence on Crithidia luciliae), anti-
smooth muscle antibodies (ASMA) 1/640 was observed,
while the titre of antinuclear antibodies (ANA), previously
present at a serum dilution of 1/80, increased to 1/160. Liver
ultrasonography showed steatosis. A liver biopsy revealed
intense and diffuse portal lymphoplasmacytic, granulocytic
inflammatory infiltration and severe interface hepatitis. Mild
periportal fibrosis was also evident (figs 1A and B).
Fluocortolone 20 mg daily was started and the joints
improved. Within a few months, transaminases declined
and finally normalised; ANA remained positive, while anti-
dsDNA and ASMA disappeared.
DISCUSSION
Feletar et al found a high incidence of liver toxicity in patients
with PsA treated with infliximab,1 even if, as Provenzano
pointed out,2 in some cases this association was debatable
because of the concomitant use of MTX and the lack of
exclusion of viral infections. In one of the largest studies on
the use of infliximab in rheumatoid arthritis (RA),3 no liver
disease was recorded, but recently two possible cases of liver
disease associated with infliximab use have been observed in
Crohn’s disease and PsA.4 5 In our patient the chronological
relationship between transaminasitis and treatment (fig 2),
linked to the peculiar histology, is suggestive of autoimmune
hepatitis induced by infliximab. The high titre of ASMA,
notoriously associated with autoimmune hepatitis,6 supports
this hypothesis.
Our patient was concomitantly treated with MTX for
almost 30 weeks. MTX can produce steatosis, fibrosis and,
ultimately, cirrhosis; its hepatotoxicity in psoriasis is well
known. A 2.5–5.0-fold increase in liver damage for psoriasis
compared with RA has been reported.7
Moreover, patients with PsA seem more prone to liver
toxicity during infliximab treatment than those with RA.1 A
dissimilar toxicity profile for disease modifying antirheu-
matic drugs in various diseases has been linked to differences
in pathophysiology, genetic background, drinking behaviour,
and age.
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However, our patient had received less than a third
(900 mg in the past 4 years) of the cumulative dose known
to be a risk for hepatic toxicity.8 In this case, infliximab might
have led to the acute damage—that is, severe portal
inflammation and initial neoductulogenesis, whereas MTX
might have been responsible for the chronic hepatic injury—
that is, mild fibrosis and steatosis. The introduction of
corticosteroids probably hastened liver recovery with sub-
sequent normalisation of transaminases.
The appearance of autoantibodies, occasionally associated
with mild and transitory autoimmune diseases, during anti-
tumour necrosis factor a treatment has been documented1 9
and reflects the complex relationship between tumour
necrosis factor a blockage and autoimmunity. This report
confirms the need to monitor liver enzymes carefully and
perform liver biopsy, if necessary, not only in patients with
PsA using combination treatment with MTX and infliximab
but also for those using infliximab alone, especially in the
presence of pre-existent serological signs of autoimmunity
such as ANA. Such signs might be a risk factor for further
development of clinical autoimmunity during infliximab
treatment.
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Figure 1 (A) A liver biopsy revealed intense and diffuse portal lymphoplasmacytic, granulocytic inflammatory infiltration and severe interface
hepatitis; Diffuse macro-microvesicular steatosis (over 60% hepatocytes), intranuclear glycogen accumulation, and hyaline degeneration of hepatocytes
(Mallory bodies) were also noted. Mild periportal fibrosis was evident with formation of incomplete septa and perisinusoidal and perivenular fibrosis.
(B) Lobular evidence of confluent necrosis and inflammatory infiltrates.
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Figure 2 Chronological relationship between transaminasitis and
infliximab in the patient. AST, aspartate aminotransferase; ALT, alanine
aminotransferase; T, time in weeks; MTX, methotrexate; CyA, ciclosporin
A; ANA, antinuclear antibodies; ASMA, anti-smooth muscle antibodies;
a-DNA, anti-DNA antibodies.
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